Dan Mirelman
- 4.5 Bom • 156 avaliações
- 21 anos de experiência
- Israel, Telavive, Sourasky Medical Center (Ichilov)
O Prof. Dr. med. Karl J. Oldhafer é especialista em cirurgias hepáticas complexas no Hospital Asklepios Barmbek, incluindo procedimentos navegados por computador e de metástases.
O Professor Associado Dr. Yusuf Acikgoz traz a sua experiência da Ohio State University – liderando agora casos de oncologia no Hospital Universitário Lokman Hekim em Ancara.
O Professor Associado Tahsin Ozatli é especialista em cancros da mama, do pulmão e gastrointestinais no Hospital Universitário Istinye Liv.
O Dr. Fox é especialista em tratamentos inovadores para o cancro do fígado, combinando quimioterapia, imunoterapia e terapias direcionadas.
O Professor Keil é especialista em radiologia diagnóstica e intervencionista avançada, incluindo diagnóstico por imagem e tratamento de cancro do fígado no Hospital Académico de Solingen.
Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.
Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.
Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.
Especializado em cirurgia laparoscópica avançada e oncológica nos prestigiados hospitais da Universidade de Istambul. Realiza técnicas minimamente invasivas para casos complexos de cancro do fígado.
Especialista no tratamento do cancro do fígado com vasta experiência em oncologia médica. O Dr. Ozden foca-se no atendimento personalizado para pacientes com cancro do fígado de estágio 3 no Hospital VM Medical Park Pendik.
O Dr. Alemdar é especialista no tratamento do cancro do fígado, com uma sólida formação académica e vasta experiência hospitalar.
Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.
Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).
Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).
Especializada em viroterapia – uma abordagem de imunoterapia de ponta para o cancro do fígado – a Dra. Jaunalksne traz mais de 30 anos de experiência em imunologia.
O Professor Associado Nail Paksoy é especialista em cancro do fígado no Hospital Medipol Bahçelievler, com vasta investigação em oncologia.
Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.
He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.
Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.
O Dr. Auala Hubert chefia o Centro de Cancro Gastrointestinal do Hadassah Medical Center, com 33 anos de experiência em oncologia e radioterapia.
O Professor Associado Babek Tabandeh é especialista em cirurgia de cancro do fígado e técnicas minimamente invasivas no Hospital Medical Park Goztepe.
Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).
She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).
Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).
He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.
Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.
Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.
He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.